Monopar Therapeutics
MNPR
6 hedge funds and large institutions have $106K invested in Monopar Therapeutics in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 7 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.03% less ownership
Funds ownership: 0.48% → 0.45% (-0.03%)
50% less funds holding
Funds holding: 12 → 6 (-6)
66% less capital invested
Capital invested by funds: $310K → $106K (-$204K)
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$6.89K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$1.71K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$145K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$34.4K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$33K |
| 4 |
GL
Gerber LLC
Columbus,
Ohio
|
-$20.4K |
| 5 |
VF
Virtu Financial
New York
|
-$14K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $94.8K | +$6.89K | +2,059 | +17% |
|
|
NA
2
NewEdge Advisors
New Orleans,
Louisiana
| $4.04K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $3.45K | +$1.71K | +512 | New |
|
4
Wells Fargo
San Francisco,
California
| $3.37K | – | – | – |
|
|
FDCDDQ
5
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $108 | – | – | – |
|
6
Bank of America
Charlotte,
North Carolina
| $88 | -$331 | -99 | -88% |
|
|
7
Millennium Management
New York
| – | -$145K | -38,860 | Closed |
|
|
TSS
8
Two Sigma Securities
New York
| – | -$34.4K | -9,412 | Closed |
|
|
9
Vanguard Group
Malvern,
Pennsylvania
| – | -$33K | -9,033 | Closed |
|
|
GL
10
Gerber LLC
Columbus,
Ohio
| – | -$20.4K | -5,601 | Closed |
|
|
VF
11
Virtu Financial
New York
| – | -$14K | -3,768 | Closed |
|
|
RRCM
12
Rappaport Reiches Capital Management
Skokie`,
Illinois
| – | -$7.81K | -2,139 | Closed |
|
|
TRCT
13
Tower Research Capital (TRC)
New York
| – | -$5.78K | -1,584 | Closed |
|
MNPR Hedge Fund Activity: Q3 2024 in Review
6 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q3 2024, worth a combined $106K — down 66% from $310K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of MNPR and 1 opened new positions — a net loss of 6 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Geode Capital Management, adding an estimated $6.89K. The largest seller was Millennium Management, exiting entirely with an estimated $145K sold.
- 6 institutional investors held Monopar Therapeutics (MNPR) as of Q3 2024, down from 12 in Q2 2024.
- Funds reported $106K of Monopar Therapeutics stock for Q3 2024, down 66% quarter-over-quarter.
- 1 fund opened new Monopar Therapeutics positions in Q3 2024 and 7 closed out, a net change of -6 holders.
- The largest Monopar Therapeutics buyer in Q3 2024 was Geode Capital Management, an estimated $6.89K added.
- The largest Monopar Therapeutics seller in Q3 2024 was Millennium Management, an estimated $145K sold.
Based on aggregated 13F filings for Q3 2024.